NextCure, Inc , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
infoNextCure is a micro cap stock with a total market cap of 43.43M.
infoThey trade on the NASDAQ and had their IPO 4 years and 3 months ago.
infoNextCure currently employs 99 people.
infoAs of Wednesday, Aug 23 2023, NextCure’s share price is $1.56.
News Relating to NextCure
GlobeNewsWire
NextCure to Present at the JMP Securities Life Sciences Conference
Tuesday May 09 2023 at 07:00
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
GlobeNewsWire
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
Tuesday Apr 11 2023 at 07:00
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
GlobeNewsWire
NextCure to Present at SVB Securities Global Biopharma Conference
Tuesday Feb 07 2023 at 07:00
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
GlobeNewsWire
NextCure to Present at Upcoming Investor Conferences
Tuesday Nov 22 2022 at 08:00
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences:
GlobeNewsWire
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
Thursday Nov 03 2022 at 09:15
BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and is being developed for the treatment of advanced myeloid leukemia (AML).
Zacks Investment Research
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
Wednesday Oct 05 2022 at 13:32
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewsWire
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
Thursday Sep 22 2022 at 08:00
BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Ladenburg Thalmann Healthcare Conference in New York City on Thursday, September 29th at 10 am ET.
GlobeNewsWire
NextCure to Present at the JMP Securities Life Sciences Conference
Wednesday Jun 08 2022 at 08:00
BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 15th at 2 pm ET.
GlobeNewsWire
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
Tuesday Feb 08 2022 at 08:00
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday February 16th at 10:40 am ET.
GlobeNewsWire
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Monday Nov 22 2021 at 08:00
BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th.
GuruFocus
2 Net Current Asset Value Stocks to Consider
Friday Oct 29 2021 at 11:00
There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation value.
GlobeNewsWire
NextCure Announces Three New Members of its Scientific Advisory Board
Tuesday Oct 19 2021 at 08:05
BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB.
GlobeNewsWire
NextCure Announces Publication of Preclinical Data for NC410
Thursday Oct 07 2021 at 16:05
BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. This immune suppression could be reversed by LAIR-2, a natural decoy of LAIR-1, and NC410, a LAIR-2 fusion protein. NC410 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors and is a first-in-class immunomedicine designed to block LAIR-1-mediated immune suppression.
GlobeNewsWire
NextCure Announces New Appointments to its Board of Directors
Monday Oct 04 2021 at 08:05
BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.
Pulse2
NXTC Stock Price: Why It Increased Over 12%
Saturday Oct 02 2021 at 14:54
The stock price of NextCure Inc (NASDAQ: NXTC) increased by over 12% in the previous trading session. This is why it happened.
GlobeNewsWire
NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting
Friday Oct 01 2021 at 08:45
BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C., and in a virtual platform on November 10-14, 2021. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a LAIR-2 fusion protein, in patients with advanced/metastatic solid tumors. In addition, in collaboration with the National Cancer Institute at the National Institutes of Health, non-clinical data will be presented from a research study evaluating NC410’s impact on T cell activation, myeloid cell polarization and anti-tumor activity.
Seeking Alpha
NextCure: Large Upside With Downside Protected By Cash Pile
Wednesday Sep 29 2021 at 08:07
The stock is left for dead, trading significantly below cash which creates a margin of safety. Significant data on all 3 drugs is due in the next 9 months.
GlobeNewsWire
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Tuesday Sep 07 2021 at 07:00
BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.
Benzinga
NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings
Wednesday Jul 07 2021 at 08:06
NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.
GlobeNewsWire
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
Tuesday Jul 06 2021 at 16:05
BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.
Benzinga
NextCure’s Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies
Tuesday Jun 22 2021 at 06:34
NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tumors.
GlobeNewsWire
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
Monday Jun 21 2021 at 16:05
BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal eLife establishing NC410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. NC410, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors, is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells.
GlobeNewsWire
NextCure to Present at the JMP Securities Life Sciences Conference
Thursday Jun 10 2021 at 16:10
BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17th at 1:30 pm Eastern time.
GlobeNewsWire
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Wednesday May 19 2021 at 18:05
BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
GlobeNewsWire
NextCure Reports First Quarter 2021 Financial Results
Thursday May 06 2021 at 17:15
BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update.
GuruFocus
A Trio of Net Current Asset Value Stock Picks
Tuesday Apr 13 2021 at 12:35
Short-term investors may want to have a look at these businesses
GlobeNewsWire
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
Saturday Apr 10 2021 at 08:30
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer.
GlobeNewsWire
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
Wednesday Apr 07 2021 at 16:05
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on April 13th at 12:45 pm Eastern time.
GlobeNewsWire
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
Tuesday Mar 02 2021 at 16:05
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.
GlobeNewsWire
NextCure to Host Virtual R&D Update Event on March 4, 2021
Friday Feb 26 2021 at 16:15
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.
NextCure Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
NextCure’s Altman Z-score is -1.53 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
NextCure Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in NextCure.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
NextCure’s Income Quality of 0.57 is lower than its Industry Group of 0.69 (-17.4% lower)
NextCure’s Income Quality of 0.57 is lower than its Major Industry Group of 0.71 (-19.7% lower)
NextCure’s Income Quality of 0.57 is lower than its Sector of 0.75 (-24.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
NextCure’s Current Ratio of 17.3 is greater than its Industry Group of 4.76 (263.4% greater)
NextCure’s Current Ratio of 17.3 is greater than its Major Industry Group of 4.32 (300.5% greater)
NextCure’s Current Ratio of 17.3 is greater than its Sector of 2.6 (565.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.64 & -1.27)
Cannot compare a negative PE Ratio (-0.64 & -1.1)
Cannot compare a negative PE Ratio (-0.64 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
NextCure’s PB Ratio of 0.31 is lower than its Industry Group of 1.34 (-76.9% lower)
NextCure’s PB Ratio of 0.31 is lower than its Major Industry Group of 1.4 (-77.9% lower)
NextCure’s PB Ratio of 0.31 is lower than its Sector of 1.62 (-80.9% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
NextCure’s ROE of -0.49 is lower than its Industry Group of -0.44 (-11.4% lower)
NextCure’s ROE of -0.49 is lower than its Major Industry Group of -0.38 (-28.9% lower)
NextCure’s ROE of -0.49 is lower than its Sector of -0.03 (-1533.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
NextCure’s ROCE of -0.5 is lower than its Industry Group of -0.42 (-19.0% lower)
NextCure’s ROCE of -0.5 is lower than its Major Industry Group of -0.37 (-35.1% lower)
NextCure’s ROCE of -0.5 is lower than its Sector of -0.04 (-1150.0% lower)
Derived from SEC.GOV filing dataopen_in_new